Evidence map›Paper›PMID 41394761›Full record

ArticleInflammatory intestinal diseases

A Retrospective Comparison of Postoperative Tumor Necrosis Factor-α Inhibitor Continuation versus Ustekinumab Switch in Crohn's Disease: Reset or Switch?

Shuhei Hosomi, Koji Fujimoto, Yumie Kobayashi, Rieko Nakata, Yu Nishida, Hirotsugu Maruyama, Masaki Ominami, Yuji Nadatani, Shusei Fukunaga, Koji Otani and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Inflammatory intestinal diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shuhei HosomiDepartment of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Koji FujimotoDepartment of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Yumie KobayashiDepartment of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Rieko NakataDepartment of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Yu NishidaDepartment of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Hirotsugu MaruyamaDepartment of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Masaki OminamiDepartment of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Yuji NadataniDepartment of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Shusei FukunagaDepartment of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Koji OtaniDepartment of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Fumio TanakaDepartment of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Yasuhiro FujiwaraDepartment of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Ustekinumab (UST) is increasingly used in Crohn's disease patients with prior tumor necrosis factor-α inhibitor (TNFi) failure. However, whether to switch to another biologic or continue TNFi therapy at the time of surgery remains an important unresolved clinical question. Methods: Among patients who underwent intestinal resection during TNFi therapy at our hospital from January 2008 to February 2022, 39 patients continued TNFi after surgery (TNFi continuation group) and 15 patients switched to UST after surgery (UST switch group) were included. Clinical and endoscopic recurrence rates were compared over long-term follow-up. Results: This retrospective cohort study showed that the cumulative 2-year clinical recurrence-free rate was 82.6% in the TNFi continuation group and 60.0% in the UST switch group, with no statistical difference in the cumulative clinical recurrence-free rate between the two groups (log-rank test; Conclusion: In patients undergoing surgery during TNFi treatment, there was no statistically significant difference between postoperative UST switching and TNFi continuation.

Indexed as

Biologic switchCrohn’s diseasePostoperative endoscopic recurrenceTumor necrosis factor-α inhibitorsUstekinumab

Identifiers

PMID41394761
PMCPMC12700595

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.